Skip to main content
Fig. 5 | Biomaterials Research

Fig. 5

From: PEG-mediated transduction of rAAV as a platform for spatially confined and efficient gene delivery

Fig. 5

Biocompatibility assessment of PEG in the brain. a Bright field of a brain slice with white arrows indicating the injecting sites. The PEG concentration of injecting solution in the left and right brain is 0 and 40% (wt/vol), respectively. Scale bar, 1 mm. b-c Immunohistochemical staining of the brain slice in a. The brain slice was prepared at 3 weeks after injections and labeled for nuclei [4′, 6-diamidino-2-phenylindole (DAPI), blue], apoptotic cells [terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), cyan], and neurons (NeuN, red). The dashed circles highlight the injection sites. Scale bars, 100 μm. d Representative movement traces of mice with injections of untreated rAAV solutions (gray) or 40% PEG-treated rAAV solutions (red) in the M2 cortex. The start and end positions are marked by blue circles and triangles, respectively. e-f Average locomotion speeds e and resting time f of the two groups of mice in (d). n = 4 mice in each group. Data are represented as mean ± SD. n.s. P > 0.5, unpaired two-tailed t-test

Back to article page